IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-09

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, multi-center, randomized trial to assess the safety and effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating patients with infrapopliteal arterial stenosis or occlusive disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical Trial

NCT05971394

Infrapopliteal Lesions Critical Limb Ischemia

RECRUITING NA

A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

NCT05206084

Coronary Artery Disease

ACTIVE_NOT_RECRUITING NA

The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients

NCT01510509

Diabetes Mellitus Percutaneous Coronary Intervention

UNKNOWN PHASE4

A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)

NCT02698852

Coronary Artery Disease

ACTIVE_NOT_RECRUITING NA

A First-in-Man Study of IBS

NCT03509142

Single Coronary Vessel Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Limb Ischemia (CLI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBS Titan

Group Type EXPERIMENTAL

Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)

Intervention Type DEVICE

Subjects in this arm will be treated with IBS Titan™.

Percutaneous Transluminal Angioplasty (PTA)

Group Type ACTIVE_COMPARATOR

Percutaneous Transluminal Angioplasty (PTA) Device

Intervention Type DEVICE

Subjects in this arm will be treated with PTA device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)

Subjects in this arm will be treated with IBS Titan™.

Intervention Type DEVICE

Percutaneous Transluminal Angioplasty (PTA) Device

Subjects in this arm will be treated with PTA device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must between 18 and 85 years old, without gender limit.
2. Patients who can understand the purpose of the trial, voluntarily participate in and sign the informed consent form, and complete the 1-year follow-up.
3. Subject has lower extremity atherosclerotic occlusive disease with symptomatic Critical Limb Ischemia (CLI).
4. Rutherford Becker Clinical Category 3-5.
5. The target lesion is below the popliteal artery (including bifurcation).
6. The target lesion is located in the proximal 2/3 of native infrapopliteal vessels or tibiofibular trunk.
7. The target lesion stenosis is ≥70% or occlusion of no more than two infrapopliteal arteries (including the anterior and/or posterior tibial and/or peroneal artery and/or tibiofibular trunk).
8. The length of target lesion is ≤200mm, which could be covered by no more than two stents, with vessel diameter of 2.25-4.25 mm.

Exclusion Criteria

1. Severe renal insufficiency, hepatic dysfunction (Cr\>2 times of normal limit or renal dialysis, ALT or AST \> 5 times of normal limit).
2. Surgery in target vessel before treatment.
3. Volume reduction surgery in target vessel before treatment.
4. Thrombosis in target vessel, or acute thrombosis requiring thrombolysis and thrombectomy.
5. Systematic coagulation disorder or hypercoagulability.
6. Lower extremity arteries surgery or thrombolytic therapy in the ipsilateral extremity in the past 6 weeks.
7. Stroke occurs within 3 months before surgery, or stroke occurs with severe hemiplegia aphasia sequelae more than 3 months before treatment.
8. Acute myocardial infarction or angina pectoris within 30 days before treatment.
9. In-stent restenosis.
10. Guide wire cannot pass target lesion.
11. Previously treated with drug eluting balloon within 1 year before treatment.
12. More than two infrapopliteal arteries needed treatment.
13. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has lumen stenosis \>30% with or without intervention.
14. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has \> 150 mm stenosis or occlusion before treatment.
15. Aneurysm of lower extremity artery.
16. Thromboangiitis obliterans (Buerger's disease).
17. Significant (≥ 50% stenosis) lesion in a distal outflow artery that would be perfused by the target vessel and that requires treatment at the time of the index procedure.
18. Patients known to be allergic to aspirin, heparin, Plavix, contrast agents, Sirolimus, poly lactic acid polymer, iron, zinc and their degradation product, and those who cannot tolerate postoperative dual anti-platelet therapy.
19. Patients who have a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc.
20. Patients who are participating in another clinical trial that has not yet completed its primary endpoint.
21. Pregnant or those who plan pregnancy during the clinical investigation follow-up period.
22. Angiography suggests intraoperative thromboendarterectomy, percutaneous transluminal rotational atherectomy or laser therapy are needed.
23. Patients have life expectancy ≤ 1 year.
24. Patients who are not suitable for participating the trial judged by investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No